Pricing Log in Create free account
Saturday 17 October 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

DexCom, Inc. 10-K filed Feb 12, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:20 PM ET · Document on sec.gov · Filing index

Red flags

  • Auditor change

    DexCom, Inc. changed auditor from Ernst & Young LLP to Deloitte & Touche LLP

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 18, 2025: 17 added · 27 removed · 64 modified; 3 with only figures updated

  1. Modified · Overview

    We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G6 integrated G7 Continuous Glucose Monitoring System, or G6G7, in 20182023, and we launched the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in 2023late 2025. In August 2024, we launched Stelo, our new biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.

107 more changes in this Item, word by word, in Powerpack.

Powerpack